Advertisement
Advertisement
INTS
Intensity Therapeutics, Inc. Common stock
0.35
USDSponsored
+0.02
+4.78%
Feb 06, 15:58 UTC -5
Closed
After-Market
0.37
+0.02
+4.79%
INTS Earnings Reports
Positive Surprise Ratio
INTS beat 6 of 10 last estimates.
60%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Intensity Therapeutics, Inc. Common stock earnings per share and revenue
On Nov 06, 2025, INTS reported earnings of -0.06 USD per share (EPS) for Q3 25, beating the estimate of -0.08 USD, resulting in a 32.81% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.22% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AYTU BioPharma, Inc. Common Stock
Report Date
Feb 03, 2026 For Q2 26
Estimate
-$0.61
Actual
-$1.05
Surprise
-71.57%
Amgen Inc
Report Date
Feb 03, 2026 For Q4 25
Estimate
$4.82
Actual
$5.29
Surprise
+9.56%
Bristol-Myers Squibb Co.
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.12
Actual
$1.26
Surprise
+11.88%
GSK plc - ADR
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.23
Actual
$0.49
Surprise
+111.36%
Biogen Inc. Common Stock
Report Date
Feb 06, 2026 For Q4 25
Estimate
$1.62
Actual
$1.99
Surprise
+22.39%
Illumina Inc
Report Date
Feb 05, 2026 For Q4 25
Estimate
$1.24
Actual
$1.35
Surprise
+8.01%
QIAGEN N.V.
Report Date
Feb 04, 2026 For Q4 25
Estimate
$0.64
Actual
$0.62
Surprise
-3.32%
Arrowhead Research Corporation
Report Date
Feb 05, 2026 For Q1 26
Estimate
$0.25
Actual
$0.22
Surprise
-14.76%
Bio-Techne Corp.
Report Date
Feb 04, 2026 For Q2 26
Estimate
$0.44
Actual
$0.46
Surprise
+3.95%
Immunovant, Inc. Common Stock
Report Date
Feb 06, 2026 For Q3 26
Estimate
-$0.72
Actual
-$0.61
Surprise
+16.27%
FAQ
What were Intensity Therapeutics, Inc. Common stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Intensity Therapeutics, Inc. Common stock reported EPS of -$0.06, beating estimates by 32.81%, and revenue of $0.00, 0% as expectations.
How did the market react to Intensity Therapeutics, Inc. Common stock's Q3 2025 earnings?
The stock price moved down -6.22%, changed from $0.49 before the earnings release to $0.46 the day after.
When is Intensity Therapeutics, Inc. Common stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Intensity Therapeutics, Inc. Common stock's next earnings report?
Based on --
analysts, Intensity Therapeutics, Inc. Common stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement